Neogenomics Inc [NASDAQ: NEO] loss -18.73% on the last trading session, reaching $5.25 price per share at the time.
Neogenomics Inc represents 128.68 million in outstanding shares, while the company has a total market value of $675.65 million with the latest information. NEO stock price has been found in the range of $4.805 to $5.64.
If compared to the average trading volume of 2.26M shares, NEO reached a trading volume of 11692045 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Neogenomics Inc [NEO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NEO shares is $9.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NEO stock is a recommendation set at 2.07. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
William Blair have made an estimate for Neogenomics Inc shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on July 29, 2025. While these analysts kept the previous recommendation, Guggenheim raised their target price to Neutral. The new note on the price target was released on May 15, 2025, representing the official price target for Neogenomics Inc stock. Previously, the target price had yet another raise to $9, while Leerink Partners analysts kept a Market Perform rating on NEO stock.
The Price to Book ratio for the last quarter was 0.79, with the Price to Cash per share for the same quarter was set at 1.27.
Trading performance analysis for NEO stock
Neogenomics Inc [NEO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.22. With this latest performance, NEO shares dropped by -26.88% in over the last four-week period, additionally sinking by -65.09% over the last 6 months – not to mention a drop of -68.14% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NEO stock in for the last two-week period is set at 25.24, with the RSI for the last a single of trading hit 0.47, and the three-weeks RSI is set at 0.43 for Neogenomics Inc [NEO]. The present Moving Average for the last 50 days of trading for this stock 7.17, while it was recorded at 6.21 for the last single week of trading, and 11.49 for the last 200 days.
Neogenomics Inc [NEO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Neogenomics Inc [NEO] shares currently have an operating margin of -12.01% and a Gross Margin at 41.52%. Neogenomics Inc’s Net Margin is presently recorded at -11.54%.
Neogenomics Inc (NEO) Capital Structure & Debt Analysis
According to recent financial data for Neogenomics Inc. ( NEO), the Return on Equity (ROE) stands at -8.57%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -4.79%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Neogenomics Inc’s Return on Invested Capital (ROIC) is -6.15%, showcasing its effectiveness in deploying capital for earnings.
Neogenomics Inc (NEO) Efficiency & Liquidity Metrics
Based on Neogenomics Inc’s (NEO) latest financial statements, the Debt-to-Equity Ratio is 0.48%, indicating its reliance on debt financing relative to shareholder equity.
Neogenomics Inc (NEO) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Neogenomics Inc. (NEO) effectively leverages its workforce, generating an average of -$35268.18 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.05% and a Quick Ratio of 1.94%, indicating strong ability to cover short-term liabilities.
Neogenomics Inc [NEO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NEO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Neogenomics Inc go to 59.48%.
An analysis of Institutional ownership at Neogenomics Inc [NEO]
There are presently around $98.24%, or 99.43% of NEO stock, in the hands of institutional investors. The top three institutional holders of NEO stocks are: BLACKROCK INC. with ownership of 19.67 million shares, which is approximately 15.5612%. VANGUARD GROUP INC, holding 14.12 million shares of the stock with an approximate value of $$195.87 million in NEO stocks shares; and VANGUARD GROUP INC, currently with $$121.66 million in NEO stock with ownership which is approximately 6.9391%.
